{"id":"NCT02201940","sponsor":"Gilead Sciences","briefTitle":"Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07","primaryCompletion":"2015-06","completion":"2015-09","firstPosted":"2014-07-28","resultsPosted":"2016-09-16","lastUpdate":"2018-11-15"},"enrollment":741,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection"],"interventions":[{"type":"DRUG","name":"SOF/VEL","otherNames":["EpclusaÂ®","GS-7977/GS-5816"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SOF/VEL","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) for 12 weeks in adults with chronic genotype 1, 2, 4, 5, or 6 hepatitis C virus (HCV) infection.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF/VEL","deltaMin":99,"sd":null},{"arm":"Placebo","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":80,"countries":["United States","Belgium","Canada","China","France","Germany","Italy","Puerto Rico","United Kingdom"]},"refs":{"pmids":["26571066","36740893","27847279"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":624},"commonTop":["Headache","Fatigue","Nasopharyngitis","Nausea","Insomnia"]}}